VBI Vaccines updates on glioblastoma vax progress; Scripps team nets $1.6M for heroin addiction vaccine;

> Cambridge, MA-based VBI Vaccines ($VBIV) said data confirm the "desired integrity and quality" of its candidate glioblastoma vaccine; it has a pre-IND meeting with the FDA in the first half of 2016. Release

> A team at The Scripps Research Institute received $1.6 million through the Translational Avant-Garde Award program to work on a vaccine to combat heroin addiction. Report

> The Sabin Vaccine Institute, through its Product Development Partnership, teamed up with King Saud University to grow vaccine research capabilities in the Middle East. Report

> Baltimore, MD-based Vaccinogen signed on with Dublin City University to get its hands on the biotechnology analysis platform DiCast. Report

> Memphis, TN-based Hapten Sciences announced it's commencing trials of its poison ivy vaccine candidate. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.